(VIANEWS) – SEADRILL (SDRL.OL), AIRBUS (AIR.PA), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SEADRILL (SDRL.OL)
70% sales growth and 4.22% return on equity
Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drill ships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was formerly known as Seadrill 2021 Limited. The company was incorporated in 2005 and is headquartered in Hamilton, Bermuda.
Earnings Per Share
As for profitability, SEADRILL has a trailing twelve months EPS of kr682.59.
PE Ratio
SEADRILL has a trailing twelve months price to earnings ratio of 0.69. Meaning, the purchaser of the share is investing kr0.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.22%.
Volume
Today’s last reported volume for SEADRILL is 33167 which is 71.67% below its average volume of 117079.
Yearly Top and Bottom Value
SEADRILL’s stock is valued at kr472.50 at 12:20 EST, way below its 52-week high of kr550.00 and way higher than its 52-week low of kr275.00.
Sales Growth
SEADRILL’s sales growth is 59.5% for the current quarter and 70% for the next.
Moving Average
SEADRILL’s value is under its 50-day moving average of kr499.82 and way higher than its 200-day moving average of kr429.35.
More news about SEADRILL.
2. AIRBUS (AIR.PA)
7% sales growth and 26.56% return on equity
Airbus SE engages in the design, manufacture, and delivery of aerospace products, services, and solutions worldwide. It operates through three segments: Airbus, Airbus Helicopters, and Airbus Defence and Space. The Airbus segment develops, manufactures, markets, and sells commercial jet passenger aircraft; freighter aircraft; and regional turboprop aircraft and aircraft components, as well as provides aircraft conversion and related services. The Airbus Helicopters segment engages in the development, manufacture, marketing, and sale of civil and military helicopters; and provision of helicopter related services. The Airbus Defence and Space segment designs, develops, delivers, and supports military aircraft, such as combat, mission, transport, tanker aircraft, and their associated services; a range of civil and defence space systems for telecommunications, earth observations, navigation, science, and orbital systems; and unmanned aerial systems. This segment also offers missile and space launcher systems, as well as services around data processing from platforms, secure communication, and cyber security. The company was formerly known as Airbus Group SE and changed its name to Airbus SE in April 2017. Airbus SE was incorporated in 1998 and is based in Leiden, the Netherlands.
Earnings Per Share
As for profitability, AIRBUS has a trailing twelve months EPS of €4.9.
PE Ratio
AIRBUS has a trailing twelve months price to earnings ratio of 25. Meaning, the purchaser of the share is investing €25 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.56%.
Volume
Today’s last reported volume for AIRBUS is 237830 which is 72.79% below its average volume of 874241.
Yearly Top and Bottom Value
AIRBUS’s stock is valued at €122.50 at 12:20 EST, way below its 52-week high of €138.76 and way higher than its 52-week low of €86.52.
More news about AIRBUS.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.32.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 73.12. Meaning, the purchaser of the share is investing kr73.12 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Volume
Today’s last reported volume for VISTIN PHARMA is 70976 which is 170.79% above its average volume of 26210.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 54.7%, now sitting on 410.31M for the twelve trailing months.
More news about VISTIN PHARMA.
4. SPAREBANKEN MØRE (MORG.OL)
6% sales growth and 11.3% return on equity
Sparebanken Møre, together with its subsidiaries, provides banking services for retail and corporate customers in Norway. It operates through Retail and Real Estate Brokerage segments. The company offers services in the areas of financing, deposits and other forms of investments, payment transfers, financial advisory services, asset management, insurance, and real estate brokerage. Sparebanken Møre was founded in 1843 and is headquartered in Ålesund, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN MØRE has a trailing twelve months EPS of kr16.2.
PE Ratio
SPAREBANKEN MØRE has a trailing twelve months price to earnings ratio of 4.83. Meaning, the purchaser of the share is investing kr4.83 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.3%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 40.7% and 0.9%, respectively.
More news about SPAREBANKEN MØRE.
